NDC 70518-2909-2 - Carbidopa and levodopa
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70518-2909
- Requested NDC
- 70518-2909-2
- Package NDCs from labels
- 70518-2909-0, 70518-2909-2, 70518-2909-1
- Manufacturer
- REMEDYREPACK INC.
- Effective date
- 2024-09-20
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Carbidopa and Levodopa Tablets, USP | REMEDYREPACK INC. | 2024-09-20 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 70518-2909-0 | 2022-02-09 | C162847 | 48780-1 | d6a99b39-7cff-a426-e053-dadaa90af4c2 | Carbidopa and Levodopa Tablets, USP |
| 70518-2909-0 | 2022-01-28 | C162847 | 48780-1 | d6a99b39-7cff-a426-e053-dadaa90af4c2 | Carbidopa and Levodopa Tablets, USP |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CARBIDOPA AND LEVODOPA | CARBIDOPA AND LEVODOPA | Sun Pharmaceutical Industries, Inc. | 829c35f9-ace0-11dd-8800-f3e252b43544 | 2021-08-13 | Warnings, Adverse reactions | MNX7R8C5VO 46627O600J |
| Carbidopa | CARBIDOPA | Aurobindo Pharma Limited | ed98c7e1-78a6-43a5-92cd-4f085af6f09d | 2021-04-29 | Warnings, Adverse reactions | MNX7R8C5VO |
| Carbidopa | CARBIDOPA TABLETS | Oceanside Pharmaceuticals | d5204e5e-10ef-4758-8fc6-cb710048c687 | 2020-07-02 | Warnings, Adverse reactions | MNX7R8C5VO |
| Lodosyn | CARBIDOPA | Bausch Health US, LLC | ff8e105b-7415-42d4-bbb2-b36cfb8945a5 | 2020-07-01 | Warnings, Adverse reactions | MNX7R8C5VO |
| Carbidopa and Levodopa | CARBIDOPA AND LEVODOPA | Alembic Pharmaceuticals Limited | a85a56c5-44dd-41d4-ac1c-bdc4758406a4 | 2019-06-06 | Warnings, Adverse reactions | MNX7R8C5VO 46627O600J |
| Neuro-Pro T007 | GABA, L-DOPA, NOREPINEPHRINE, SEROTONIN, ADRENOCORTICOTROPHIN, ANACARDIUM ORIENTALE, ARSENICUM ALBUM, BARYTA CARBONICA, CALCAREA CARBONICA, CALCAREA PHOSPHORICA, HYOSCYAMUS NIGER, LYCOPODIUM CLAVATUM, STRAMONIUM | Guangzhou Renuma Medical Systems Co., Ltd | 7e02ab0c-9bc2-4ffe-926c-5b388a07f7b2 | 2017-10-18 | Warnings | 46627O600J |
| Carbidopa | CARBIDOPA | Novel Laboratories, Inc. | 7e5c9666-7a7c-4b64-87e4-7be6ae53603e | 2017-06-01 | Warnings, Adverse reactions | MNX7R8C5VO |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.